ACC Kinder

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of ACC Kinder

Quick Facts

Property Description
Active ingredient Acetylcysteine (N-acetylcysteine)
Form Oral solid preparation (Effervescent tablets/granules)
Pharmacological class Mucolytic agent, Secretolytic
Common use Reducing thickness of respiratory mucus
Origin Synthetic L-cysteine derivative

What Kind of Medicine is ACC Kinder?

ACC Kinder is a proprietary medicinal formulation adapted for pediatric patients, specifically classified as a mucolytic and secretolytic agent. The medicine’s single active component is Acetylcysteine (N-acetylcysteine, NAC), an established compound recognized for its role in respiratory medicine. Acetylcysteine is a synthetic drug, chemically a derivative of the naturally occurring amino acid, L-cysteine. As an active thiol compound, its primary therapeutic role is facilitating the liquefaction and removal of excessive, thickened respiratory secretions, which distinguishes it from general cough suppressants. Pharmacological data supports the bioavailability of effervescent Acetylcysteine formulations, demonstrating reliable systemic delivery.

Composition and Pharmaceutical Form of ACC Kinder

ACC Kinder is a single active ingredient product formulated as an oral solid preparation, primarily effervescent tablets or granules for making an oral solution. This choice of dosage form is designed to provide ease of oral administration, particularly for the pediatric target audience implied by the "Kinder" designation. The product’s composition includes the active Acetylcysteine integrated into an effervescent matrix, typically comprising excipients like citric acid and sodium bicarbonate, which ensures the substance dissolves rapidly in water before ingestion. This oral preparation ensures the active substance is readily available for absorption and function.

General Purpose and Action on Mucus

The general purpose of ACC Kinder is to support the body’s natural clearance mechanisms by chemically reducing the viscosity, or thickness, of phlegm. Acetylcysteine achieves this through a direct physiological action: it utilizes its free thiol groups to cleave the disulfide bonds that stabilize the complex structure of the mucus proteins, a process known as depolymerization. By actively thinning these tenacious secretions, the drug enables the cough reflex to be more productive and less strenuous, ultimately helping to clear the airways and ease the sense of congestion in the lungs. The substance is noted for its significant pharmacological benefit in conditions involving excessive mucous secretion.

Regulatory References

  1. N-Acetylcysteine - StatPearls - NCBI Bookshelf

What side effects are possible with ACC Kinder?

Possible Side Effects and Safety Information

The official safety information for acetylcysteine (the active substance in ACC Kinder) categorizes documented side effects based on how often they have been reported in clinical experience and post-marketing surveillance.

Documented Adverse Reactions

Classification by Frequency (as documented) System Organ Class (SOC) Examples of Reported Reactions
Infrequently Reported Gastrointestinal Disorders Nausea, heartburn, vomiting
Nervous System Disorders Headache, ringing in the ears (tinnitus)
Rarely Reported Skin and Subcutaneous Tissue Disorders Allergic skin reactions (itching, hives/urticaria)
Immune System Disorders Bronchospasm (especially in patients with asthma)

Serious Reactions and Limitations

Serious adverse reactions have been documented in regulatory sources, though rarely. These include bronchospasm and more severe allergic skin reactions. The active substance, when administered intravenously at high doses, has also been linked to anaphylactoid reactions.

Safety-Related Restrictions

Use of this medicine is contra-indicated (must not be used) in patients who are known to be hypersensitive to the active substance, acetylcysteine, or who have active peptic ulceration.

Population-Specific Safety Considerations

The regulatory documents include specific cautions regarding patient populations, stating that the medicine should be given to new-born infants only if absolutely necessary.

Due to the presence of sucrose, the medicine is restricted for use in patients with rare hereditary problems such as fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency. This content also requires consideration when treating diabetic patients.

Drug Interaction Note

Concomitant use with most oral antibiotics may result in a reduction of the effectiveness of the antibiotic. Official labeling instructs that oral antibiotics should be taken at least 2 hours before or 2 hours after taking this medicine to mitigate this known interaction.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented overdose information for Acetylcysteine (the active ingredient in ACC Kinder) as described in government regulatory labeling.

Category Official Regulatory Statement
Documented Overdose Presentations Overexposure typically results in gastrointestinal symptoms such as nausea, vomiting, and diarrhea. Other regulator-listed signs include headache and tinnitus in certain contexts.
Physiological Systems Affected High, prolonged exposure is associated with the potential for hepatic and renal adverse effects. Severe overdose is classified as potentially life-threatening, impacting the cardiovascular and respiratory systems, sometimes leading to severe hypotension or cardiorespiratory arrest.
Immediate Action Required The regulatory instruction is to seek immediate medical attention for suspected overdose or the manifestation of severe adverse reactions. Individuals must contact emergency services or a regional poison center immediately.

Overdose Context and Management

No specific antidote is known for overdose involving the mucolytic formulation. Management is primarily symptomatic and supportive treatment. Procedural steps such as gastric lavage may be considered if initiated shortly after ingestion. Hospital monitoring is required following a significant overdose for clinical assessment and observation of potential systemic complications. Special attention is directed toward adjusting total fluid volume when managing overdose in pediatric patients to prevent the risk of fluid overload.

Therapeutic Uses of ACC Kinder

What ACC Kinder Treats: Main Uses and Benefits

The primary therapeutic role of ACC Kinder is to provide targeted symptomatic relief in the airways by managing symptoms related to excessively thick and sticky respiratory mucus. It is used to offer supportive therapeutic benefit in clinical settings marked by the production of tenacious phlegm. This therapeutic role is applied in situations to help ease chest congestion due to thick or abnormal mucous secretions in various lung conditions.


Therapeutic Support and Symptom Management

This medication is commonly used across conditions characterized by episodic or fluctuating symptom patterns, including chronic bronchopulmonary diseases (such as chronic bronchitis) and during acute respiratory episodes like pneumonia. It is also relevant for specialized patient groups managing conditions like cystic fibrosis or requiring tracheostomy care.

The therapy is generally applied to support the body's clearance mechanisms, thereby assisting the process of expelling retained secretions.

This medicine is considered relevant for symptomatic support by assisting the secretions to achieve a consistency that is easier to expectorate, which contributes to improved day-to-day comfort during periods of heightened symptoms.


Quick Fact: Relief for Thick Mucus Symptom Type Therapeutic Aim Clinical Context
Viscid Phlegm Easing Expectoratory Difficulty Acute & Chronic Respiratory States
Retained Secretions Supportive Airway Clearance Pediatric & Specialized Care

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility to use ACC Kinder (oral acetylcysteine) is strictly determined by regulatory rules concerning age, patient hypersensitivity, and specific pre-existing conditions. These rules define who is allowed, restricted, or prohibited from using the medicine.

Age and Absolute Contraindications

The medicine is contraindicated and must not be used in children under 2 years of age. This prohibition is based on the physiological risk of airway obstruction by mucolytics in infants who cannot effectively clear thickened secretions. It is also strictly contraindicated for patients with known hypersensitivity to acetylcysteine or any excipient, or those with active peptic ulceration. Use in children aged 2 to 5 years requires specific lower strengths and medical supervision. Standard strengths are generally approved for adolescents and adults.

Eligibility Status Summary

Eligibility Status Key Restriction
Contraindicated Children under 2 years; Hypersensitivity; Active Peptic Ulcer.
Restricted Use with caution in patients with bronchial asthma (stop if bronchospasm occurs) or a history of peptic ulcer.
Conditional Pregnancy (preferable to avoid); Lactation (benefit/risk assessment required).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of ACC Kinder (Acetylcysteine) is defined by specific regulatory constraints concerning co-administered substances, focusing on pharmacodynamic conflicts and timing requirements.


Prohibited Combinations and Pharmacodynamic Effects

Co-administration with antitussive drugs (cough suppressants) is formally prohibited. This regulatory restriction is due to a pharmacodynamic conflict where the cough reflex is suppressed, leading to the risk of accumulation and retention of the liquefied bronchial secretions. A different type of pharmacodynamic interaction occurs with Nitroglycerin, as Acetylcysteine enhances its vasodilatory effects. This combination may result in clinically significant hypotension (low blood pressure) and potential headache.


Mandatory Separation and Exposure Interference

Administration of oral antibiotics, including cephalosporins and tetracyclines, must be separated by at least two hours. This mandatory timing rule prevents the chemical inactivation of the antibiotic that can occur when the two substances are co-administered. The effectiveness of Acetylcysteine may also be reduced by Activated Charcoal, which interferes with its gastrointestinal absorption, leading to a decrease in its systemic exposure. Separately, regulatory information notes that chronic consumption of Ethanol (Alcohol) is associated with an increased risk of toxicity in related therapeutic contexts.

Mechanism of Action

Ontology: How ACC Kinder works

The drug's action relies on two distinct mechanistic domains: direct chemical mucolysis and metabolic precursor activity.

Direct Chemical Breakdown of Mucus

The active ingredient contains a free sulfhydryl group that acts as a chemical de-linker. This group targets and chemically cleaves the disulfide bonds ( S- S) that cross-link the large mucoprotein chains (mucins) in respiratory secretions. This mechanistic step dismantles the sticky gel structure of the mucus, resulting in a reduction in its viscosity and elasticity, a physiological consequence that facilitates the removal of secretions from the airways.

Role as Precursor in Antioxidant Pathways

The molecule provides the necessary precursor, L-cysteine, which is the rate-limiting step in the synthesis of Glutathione (GSH), a major endogenous antioxidant. By replenishing intracellular GSH reserves, the mechanism modulates the Redox Regulation pathway, facilitating the neutralization of reactive oxygen species (ROS) and contributing to the stability of the airway lining structure.

Dosage and Administration Information

ACC Kinder, which contains Acetylcysteine, is officially used via two primary administration routes: Oral (as a solution prepared from its effervescent form) and Intravenous (IV) Infusion.

For mucolytic support, the standardized adult dosing regimen often consists of 200 mg administered three times per day, totaling a maximum 600 mg daily dose. The effervescent contents must be dissolved completely in water just prior to ingestion and should not be combined with other medicinal products. Official recommendations state that abundant fluid intake is recommended to support the medicine’s action.

For its use as an antidote in acute settings, the drug follows a rigid, 21-hour structured course. The Intravenous protocol delivers a total of 300 mg/kg over three sequential infusions (1 hour, 4 hours, and 16 hours), a schedule defined in official prescribing guidelines. Alternatively, the official oral regimen involves a 140 mg/kg loading dose followed by seventeen 70 mg/kg maintenance doses.

Crucially, specific instructions govern its use in certain populations: the 200 mg effervescent forms are officially stated as unsuitable for use in children under 12 years of age. Furthermore, in the pediatric IV regimen, although children receive the same mg/kg dose as adults, the volume of diluting fluid must be carefully restricted to adhere to fluid-volume administration constraints.

Recent Clinical Evidence

ACC Kinder: Research Evidence Overview

The research for Acetylcysteine, the active ingredient in ACC Kinder, has explored its use in conditions associated with thick or excessive respiratory mucus. Clinical evaluation of this compound was studied in research contexts involving both short-term illnesses and longer-term, chronic lung conditions. The evidence highlights what is known — and what is still uncertain — according to authorized scientific sources.


Evidence for Acute Respiratory Conditions with Viscid Secretions

Research exploring short-term symptom changes was evaluated in patients experiencing acute illnesses, such as bronchitis, where thick secretions are present. Studies explored outcomes related to physical discomfort, cough intensity, and measures of mucus expectoration in adult and older pediatric patients. Scientific reviews note that findings were mixed across various short-term trials regarding outcomes like the total duration of the illness. Data for very young children (under two years old) remain insufficient, and follow-up durations were typically limited to the acute phase.


Evidence for Chronic Bronchopulmonary Disease Support

Longer-term trials examined outcomes reflecting daily functioning and the frequency and severity of disease exacerbations in chronic conditions like Chronic Bronchitis and Cystic Fibrosis. Studies explored sustained use and examined outcomes related to lung function stability over months or years. A limitation is that much of the long-term evidence was observed in adult cohorts, and data specifically tailored to younger pediatric patients with chronic disease is limited.


Research for Specialized Airway Clearance

Specialized clinical research was studied for patients in critical care settings, including those requiring mechanical ventilation. These studies examined outcomes monitoring physiological strain and the duration of mechanical support. Scientific reviews note that findings were mixed regarding major clinical outcomes. Certainty remains low due to small sample sizes, heterogeneity across trials, and the lack of high-quality, large-scale studies.


Research Gaps and Follow-Up

Scientific bodies consistently note that long-term effects are not fully established in all pediatric populations. Research continues to explore the durability of observed patterns. The overall evidence quality varies across studies, and data for infants and very young children remain insufficient across both acute and chronic contexts.

Key Studies & References

  1. N-acetylcysteine Treatment in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis/Pre-COPD: Distinct Meta-analyses

Frequently Asked Questions (FAQ)

Common questions about ACC Kinder (FAQ)


Q: Are there any common foods or drinks that should be avoided while taking ACC Kinder?

Official prescribing information indicates that this medicine can be taken with or without food, as co-administration does not affect its effectiveness. For administration, the effervescent product may be dissolved in common liquids such as water, juice, soft drinks, or chocolate milk.


Q: Can a patient take ACC Kinder if they are allergic to sulfur or sulphites?

Official product information states that hypersensitivity to the active ingredient, acetylcysteine, is a contraindication. However, the information does not typically establish a link or cross-reactivity between this medication and allergies to sulfonamide antibiotics (often referred to as sulfa allergy).


Q: Does ACC Kinder cause drowsiness?

Drowsiness has been reported as an adverse reaction of the active substance in some regulatory documents. A change in alertness, if observed, is a factor to be considered by the supervising healthcare provider.


Q: Can ACC Kinder be mixed with milk or juice?

Official administration guidance specifies that the medicine may be mixed with various liquids for ingestion, including water, juice, soft drinks, or chocolate milk.


Q: Are there different forms of ACC Kinder, like syrup, powder, or tablets?

ACC Kinder is typically provided as an oral solid preparation, such as effervescent tablets or granules, which are dissolved to create a solution. Other oral solution presentations of the active ingredient are available and often considered for pediatric patients, especially those who cannot take the effervescent form.


Q: Does ACC Kinder contain any sugar, artificial sweeteners, or common allergens?

Official documents state the formulation contains specific non-active ingredients, or excipients, such as sucrose, lactose, and sorbitol. Due to the presence of these substances, the medicine has restrictions for use in patients with rare hereditary problems such as lactose intolerance or glucose-galactose malabsorption.


Q: Are there specific symptoms that mean a person should stop taking ACC Kinder immediately?

Official prescribing information indicates that the medicine is typically discontinued immediately if severe symptoms such as bronchospasm (a sudden tightening of the airways) occur. The document also notes that treatment may be stopped if signs of a rare allergic reaction, such as generalized urticaria (hives), appear.


Q: Why do some forums suggest using ACC Kinder for ear infections?

Official indications for this medicine, as defined by regulatory bodies, are limited to its use as a mucolytic agent to thin mucus in respiratory conditions and as an antidote for acetaminophen overdose. It is not indicated or approved for the treatment of ear infections.


Q: Is ACC Kinder the same as regular ACC, just a smaller dose?

ACC Kinder is a formulation of the active ingredient that is specifically adapted for pediatric patients. This typically means the product comes in a lower strength or a different dosage form compared to standard adult presentations.


Q: How quickly does ACC Kinder start working after taking it?

Regulatory-reviewed studies on the active ingredient show that the maximum concentration in the blood plasma is typically achieved within one to two hours following an oral dose.


Q: Does taking ACC Kinder affect the results of any common medical tests?

Regulatory information notes that the active substance may interfere with the colorimetric assay methods used to determine certain substances in the body, such as salicylates. It can also interfere with tests used to check for ketones in urine.


Q: Is ACC Kinder available over the counter or does it always require a prescription?

The classification of the active substance, acetylcysteine, as a medicine varies internationally. In some countries, it is authorized as a prescription-only medicine (POM), while in others, it is available over-the-counter (OTC) or as a nutritional supplement.


Q: What happens if I forget to give a dose of ACC Kinder?

Instructions for a missed dose generally advises administering the dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the regulatory document advises skipping the missed dose and resuming the regular schedule. The guidance specifies that a double dose should not be administered to compensate for the missed one.


Q: Are there any known interactions between ACC Kinder and common painkillers like paracetamol?

Official interaction lists do not typically specify an interaction between acetylcysteine when used as a mucolytic and common painkillers such as paracetamol (acetaminophen). Regulatory guidelines expect that a full list of medications being taken is disclosed to the prescribing clinician.


Q: What is the expected length of time someone typically uses ACC Kinder?

For symptomatic treatment of acute conditions, the official prescribing information describes a typical usage limit of 8 to 10 days. The document specifies that use continuing beyond this period is subject to consultation with a medical professional.


Q: Is it normal if the cough seems slightly worse right after starting ACC Kinder?

Regulatory information notes that the active ingredient may liquefy bronchial secretions and increase their volume, especially when treatment begins. Increased coughing is listed as a common effect, as the body works to clear the newly thinned mucus from the airways.


Q: Can ACC Kinder affect a child's sleep patterns?

Drowsiness has been reported as an adverse reaction of the active substance in some regulatory documents. Changes in sleep or alertness, if observed, are a factor to be considered by the supervising healthcare provider.


Q: Where can I find the official regulatory information (like the package leaflet) for ACC Kinder?

Official regulatory information for a specific product is generally found in documents such as the Summary of Product Characteristics (SmPC) in Europe or the Medication Guide/Prescribing Information in the United States. These documents provide comprehensive, factual details about the medicine.


Q: How soon after stopping ACC Kinder will the drug be completely out of the child's system?

Regulatory-reviewed information provides the terminal half-life of the active substance, which is reported to be approximately 6.25 hours. Pharmacokinetic principles suggest it generally takes multiple half-lives for the drug to be fully eliminated from the system.


Q: Is there a maximum number of days ACC Kinder should be used continuously?

For symptomatic treatment of acute conditions, the official prescribing information describes a typical usage limit of 8 to 10 days. The document specifies that use continuing beyond this period is subject to consultation with a medical professional.


Q: Does ACC Kinder have any preservatives or colorings?

The Summary of Product Characteristics (SmPC) lists the specific non-active ingredients (excipients), which typically include sucrose, lactose, and sorbitol for the oral solid forms. Certain solutions of the active ingredient used in other contexts are regulated as preservative-free.


Q: Does the efficacy of ACC Kinder change if it's taken before or after a meal?

Official prescribing information notes that the effectiveness (efficacy) of the medicine is not affected when taken with or without food.


Q: Is ACC Kinder safe to use alongside multivitamin supplements?

Multivitamin supplements are not typically included on official regulatory interaction lists as products that must be separated from or avoided when taking this medicine.


Q: Does ACC Kinder have a known impact on liver function?

While the active ingredient is used in a high-dose capacity as an antidote for acetaminophen overdose (a condition that affects the liver), regulatory side effect lists for its mucolytic use do not typically list liver dysfunction as a commonly reported adverse reaction.


Q: Are there differences in the approved uses of ACC Kinder across different countries?

The regulatory classification of the active substance differs between international jurisdictions. In some countries, it is authorized exclusively as a prescription medicine, while in others, it is also available as a non-prescription supplement.

How should ACC Kinder be stored and disposed of?

The storage and disposal of ACC Kinder (Acetylcysteine) must adhere to official regulatory conditions to ensure stability and public safety.

Storage Conditions

Storage Requirement Official Condition
Temperature Store unopened product at Controlled Room Temperature (20 C to 25 C), protected from excess heat.
Protection Keep the medicine in its original container, tightly closed, and away from moisture and light.
Child Safety Must be kept out of the sight and reach of children in a secure location.
Stability Limit The solution prepared from the granules must be used immediately and not stored.

️ Disposal Requirements

Unused or expired product must be disposed of in accordance with local regulations. Medicines should not be flushed down the toilet or thrown into household trash unless specific disposal instructions permit it. Patients should return expired medicines to a pharmacy or drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of ACC Kinder found in:

A-Z Index: